June 2025 Updates

from OncoPharm · host John Bossaer

A plethora of recent updates: -Pembrolizumab (perioperative) in head & neck cancer (Keynote-689) -Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib -Pirtobrutinib improves PFS in CLL -Zanubrutinib has a new dosage form on the way -Another mitomycin product approved with "reverse thermal properties" -A new regimen for FL of tafasitamab/rituximab/lenalidomide -A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

Episode metadata supplied by the publisher feed · Published Jun 19, 2025

Embed this episode

Attribution link and audio player

Ready to play

June 2025 Updates

0:00 27:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 27 minutes long.

When was this OncoPharm episode published?

This episode was published on June 19, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!